Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Sona Nanotech Inc. (C:SONA)

Business Focus: Medical Equipment, Supplies & Distribution (NEC)

Mar 25, 2024 09:27 am ET
Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results
Halifax, Nova Scotia--(Newsfile Corp. - March 25, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). An update received by the Company indicates that all tumors treated within the Study to date with a single Targeted Hyperthermia Therapy ("THT") treatment shrunk within the first 24 hours, with an average reduction in size of 80% compared to matched controls.
Mar 18, 2024 09:21 am ET
Sona Nanotech Announces Filing of Provisional Patent Application
Halifax, Nova Scotia--(Newsfile Corp. - March 18, 2024) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has submitted a provisional patent application with the United States Patent and Trademark Office (USPTO), for its proprietary photothermal light device, entitled, "ENDOSCOPE WITH EMR OPTICAL FIBER AND THERMAL SENSOR FOR PHOTOTHERMAL THERAPY".
Mar 01, 2024 09:03 am ET
Sona Nanotech Grants Options
Halifax, Nova Scotia--(Newsfile Corp. - March 1, 2024) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that that it has granted 1,195,000 incentive stock options under the Company's Stock Option Plan ("Option Plan"), of which 810,000 have been granted to a Directors and Officers. Each option is exercisable into one common share at a price of $0.31 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company's Stock Option Plan.
Jan 10, 2024 08:55 am ET
Sona Nanotech Announces Director Retirement
Halifax, Nova Scotia--(Newsfile Corp. - January 10, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces that Dr. Michael Gross has retired from the Company's Board of Directors (the "Board") to focus on other business interests.
Nov 27, 2023 08:59 am ET
Sona Nanotech Closes Private Placement Financing to Raise $750,000 in Gross Proceeds and Announces Additional Financing
Halifax, Nova Scotia--(Newsfile Corp. - November 27, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has closed its private placement that was announced on October 18, 2023 with the issuance of 3,750,000 shares at $0.20 per share and 1,875,000 common share purchase warrants exercisable to purchase an additional common share of Sona at a price of $0.30 per share until November 24, 2025. (the "Financing"). Insiders subscribed for 175,000 common shares and 87,500 common share purchase warrants. As previously disclosed, Sona intends to use the net proceeds of the Financing for further research and development of its Targeted Hyperthermia TherapyTM ("THT"), as well as for general working capital purposes.
Oct 18, 2023 08:36 am ET
Sona Nanotech Arranges Brokered Private Placement Financing
Halifax, Nova Scotia--(Newsfile Corp. - October 18, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that it plans to raise up to $750,000 through a brokered private placement (the "Financing") of up to 3,750,000 units of Sona (each, a "Unit") at $0.20 per Unit (the "Offering Price"). Each Unit will consist of one common share of Sona (a "Common Share") and one-half (1/2) of a common share purchase warrant (each whole warrant, a "Warrant"). Each whole Warrant will be exercisable to purchase one additional Common Share of Sona at a price of $0.30 per share for a period of 24 months from the closing date of the Financing (the "Closing Date"). Insiders and certain other existing shareholders of Sona may also subscribe for Units under the Financing.
Oct 12, 2023 01:21 pm ET
Sona Provides Corporate Update on Operating Activities
Halifax, Nova Scotia--(Newsfile Corp. - October 12, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona"), a nanotechnology life sciences company with proprietary manufacturing technology for biocompatible gold nanorods ("GNRs"), is pleased to provide an update on the status of its current operating activities, notably the development of its Targeted Hyperthermia Therapy ("THT") therapy and its rapid bovine tuberculosis prototype test.
Sep 11, 2023 08:50 am ET
Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study
Halifax, Nova Scotia--(Newsfile Corp. - September 11, 2023) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce an innovative research initiative to be undertaken with The Giacomantonio Immuno-Oncology Research Group (the "Research Group"). This study aims to evaluate the efficacy of Sona's Targeted Hyperthermia Therapy ("THT") technology in not only attenuating the development of colorectal, breast, and melanoma tumor models in mice but also in facilitating systemic immune responses.
Sep 05, 2023 09:31 am ET
Sona to Engage with Medical Experts and Payors to Inform Regulatory and Commercialization Strategies for Its 'THT' Cancer Therapy
Halifax, Nova Scotia--(Newsfile Corp. - September 5, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce it has partnered with EXCITE International ("EXCITE"), a global network of senior specialist physicians, payors, health systems, and end-users, to help guide the development of Sona's Targeted Hyperthermia Therapy. Through this partnership with EXCITE, Sona will gain access to EXCITE's global network to help it align pre-clinical and clinical trial design and regulatory strategy with the interests of specialist practitioner and potential payor groups.
Jul 11, 2023 08:50 am ET
Sona Nanotech Grants Options
Halifax, Nova Scotia--(Newsfile Corp. - July 11, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF), (the "Company") is pleased to announce that it has granted 900,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") of which 825,000 have been granted to a Directors and Officers. Each option is exercisable into one common share at a price of $0.25 per share. 600,000 options will vest at the rate of 25% every six months and 300,000 options issued to Officers are performance-based options tied to specific goals of the Targeted Hyperthermia Therapy program. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company's Option Plan.
Jun 22, 2023 07:34 am ET
Sona Nanotech "building a mountain of data" to support use of proprietary gold nanorods
Sona Nanotech Inc. (CSE: SONA, OTCQB: SNANF) CEO David Regan speaks to Thomas Warner from Proactive about his ambitious plans for the Canadian company's proprietary gold nanorods.
Jun 08, 2023 09:39 am ET
New NCL Assessment of Sona's GNR Technology Highlights Process Improvement Success
Halifax, Nova Scotia--(Newsfile Corp. - June 8, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has received the third set of results of an independent assessment of its proprietary gold nanorod nanoparticles from the U.S. National Cancer Institute's Nanotechnology Characterization Laboratory ("NCL"). In addition to running similar assessments to those that have been previously announced for contamination and endotoxin levels, this assessment included an analysis of the surfactant residue present following the chemical reaction necessary for the manufacture of Sona's proprietary gold nanorods. The assessment shows that the continued improvements in Sona's manufacturing process for gold nanorods have resulted in a significant reduction in free surfactant levels in nanorod dispersions, with the average dropping from 230.7 ug/mL in prior assessed batches to 34.6 ug/mL in the batches following the process changes. As with the NCL's prior assessments of earlier batches of Sona's gold nanorods, this new assessment did not detect any endotoxins or microbial contamination.
May 30, 2023 08:19 am ET
Sona Nanotech Selects Minnetronix to Engineer Its Next Generation Targeted Hyperthermia Cancer Therapy Light Device
Halifax, Nova Scotia--(Newsfile Corp. - May 30, 2023) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona"), a nanotechnology company developing pre-clinical Targeted Hyperthermia Therapy ("THT") for colorectal cancer, is pleased to announce the selection of Minnetronix Medical to engineer the next generation of its infrared light device. The device will be used in Sona's development of THT to transfer energy by way of infrared light to Sona's proprietary, biocompatible gold nanorods in tumors which will then convert the light energy into heat. The light device is being designed to fit in the auxiliary channel of the sigmoidoscopes and colonoscopes used by oncology gastroenterologists.
May 18, 2023 08:41 am ET
Sona Nanotech Elects New Board Chair and is Awarded Patent
Halifax, Nova Scotia--(Newsfile Corp. - May 18, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona"), a nanotechnology company developing pre-clinical Targeted Hyperthermia Therapy for colorectal cancer, is pleased to announce the election as chair of the board, Mr. Mark Lievonen, CM, who joined the board of Sona in December 2020. Mr. Lievonen served as president of Sanofi Pasteur Limited from 1999 to 2016, during which time it became a billion-dollar enterprise in Canada, manufacturing over 50 million doses of vaccines for both domestic and international markets. A corporate director and principal of JML Advisory Services, Mr. Lievonen also co-chairs Canada's COVID-19 Vaccine Task Force.
May 09, 2023 09:00 am ET
Sona's Interest in Legacy Crescent Lake Lithium Property Sold to Midex Resources
Halifax, Nova Scotia--(Newsfile Corp. - May 9, 2023) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that an agreement for the sale of its non-core interest in the Crescent Lake lithium property located in Ontario, Canada ("Property") to an arm's length party, Midex Resources Ltd. ("Midex"), has been finalized ("Midex Agreement" or "Transaction").
Apr 17, 2023 08:45 am ET
Positive Results of Second Assessment of Sona's GNR Technology from U.S. Nanotechnology Characterization Laboratory
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.
Apr 13, 2023 08:35 am ET
Sona Nanotech Secures Bentley Biomedical as Regulatory Affairs Advisor for its THT Colorectal Cancer Therapy Development
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021
Mar 29, 2023 08:56 am ET
Sona Nanotech Grants Options
Halifax, Nova Scotia--(Newsfile Corp. - March 29, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF), (the "Company") is pleased to announce that it has granted 1,225,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") of which 1,175,000 have been granted to a Directors and Officers. Each option is exercisable into one common share at a price of $0.17 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company's Stock Option Plan.
Mar 23, 2023 08:32 am ET
Sona Nanotech Closes Acquisition of Siva Therapeutics, Plans For First Therapy Application for Colorectal Cancer
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.
Mar 06, 2023 08:54 am ET
Sona Nanotech Receives Waiver on Requirement to Raise Additional Equity Capital
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.
Feb 24, 2023 04:18 pm ET
Sona Nanotech Closes Non-Brokered Private Placement Financing to Raise $1.1M in Gross Proceeds
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.
Feb 21, 2023 08:37 am ET
Sona Nanotech to Increase Size of Equity Financing
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.
Feb 08, 2023 08:01 am ET
Sona Nanotech Receives Technology Assessment Results from NCL
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.
Jan 27, 2023 06:51 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Jan. 27, 2023 /CNW/ - Trading resumes in:
Jan 26, 2023 05:34 pm ET
Sona Nanotech to Acquire Cancer Therapy Developer Siva Therapeutics
Halifax, Nova Scotia--(Newsfile Corp. - January 26, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has entered into a binding agreement (the "Definitive Agreement") on January 26, 2023 to acquire Siva Therapeutics, Inc. ("Siva"), the developer of Targeted Hyperthermia Therapy™ ("THT") photo thermal therapy for cancer tumors using Sona's uniquely biocompatible gold nanorods (the "Proposed Transaction"). Siva holds two patents supporting the in vivo delivery of a thermal therapy, which is being designed to have multiple beneficial effects on tumors, including being more selective than chemotherapy, less destructive than radiation, and without the risks of surgical treatment. Under the Definitive Agreement, Sona has agreed to acquire all of the issued and outstanding common shares of Siva with total consideration to the Siva shareholders of US $2.0 million in Sona shares (the "Transaction Shares") at the date of closing (the "Closing Date"), plus up to an additional US $6.65 million in Sona shares over multiple instalments conditional on Siva's future achievement of specific performance milestones by January 31, 2025 (the "Performance Shares").
Jan 26, 2023 02:01 pm ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Jan. 26, 2023 /CNW/ - The following issues have been halted by IIROC:
Nov 08, 2022 08:25 am ET
Sona Signs MOU for Bovine TB Test Development and Commercialization
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021
Oct 20, 2022 09:02 am ET
Sona Announces Commercial Agreement with Siva Therapeutics
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021, to its short form base prospectus dated March 31, 2021.
May 19, 2022 05:27 pm ET
Sona Provides Corporate Update
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021
Jan 05, 2022 08:42 am ET
Sona Announces Appointment of Two New Directors, Debt Settlement and Option Grant
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021
Nov 18, 2021 08:02 am ET
Sona Announces Research Collaboration with University of Toronto's Institute of Biomedical Engineering
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.
Nov 12, 2021 04:15 pm ET
Sona Nanotech Grants Options
Halifax, Nova Scotia--(Newsfile Corp. - November 12, 2021) - Sona Nanotech Inc. (CSE: SONA) (the "Company") is pleased to announce that it has granted 1,000,000 incentive stock options to Officers and Directors under the Company's Stock Option Plan ("Option Plan"). Each option is exercisable into one common share at a price of $0.44 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company's Stock Option Plan.
Nov 08, 2021 03:27 pm ET
Sona Announces U.S. Partnership and Preliminary Evaluation Results for Its COVID-19 Saliva Test
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021
Nov 08, 2021 03:10 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Nov. 8, 2021 /CNW/ - Trading resumes in:
Nov 08, 2021 08:40 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Nov. 8, 2021 /CNW/ - The following issues have been halted by IIROC:
Sep 29, 2021 03:57 pm ET
Sona Nanotech Grants Options
Halifax, Nova Scotia--(Newsfile Corp. - September 29, 2021) - Sona Nanotech Inc. (CSE: SONA) (the "Company") is pleased to announce that it has granted 335,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") of which 300,000 have been granted to a Director. Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company's Stock Option Plan.
Sep 23, 2021 09:15 am ET
Sona Updates on Strategy and Test Development Progress
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021
Jun 11, 2021 08:58 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, June 11, 2021 /CNW/ - Trading resumes in:
Jun 11, 2021 08:43 am ET
Sona Discontinues Clinical Trial for COVID-19 Rapid Saliva Test
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.
Jun 11, 2021 08:23 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, June 11, 2021 /CNW/ - The following issues have been halted by IIROC:
May 20, 2021 09:00 am ET
Sona Nanotech Approved for Funding Support to Develop a Bovine Tuberculosis Rapid Test
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.
Apr 22, 2021 04:50 pm ET
Sona to Commence Clinical Trial for COVID-19 Rapid Saliva Test
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.
Apr 12, 2021 09:13 pm ET
Sona Secures Clinical Trial Authorization and Hospital Partner
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.
Apr 09, 2021 07:53 pm ET
Sona Establishes an At-The-Market Common Share Offering
Halifax, Nova Scotia--(Newsfile Corp. - April 9, 2021) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") a developer of rapid, point-of-care diagnostic tests announces that pursuant to an equity distribution agreement (the "Equity Distribution Agreement") with Canaccord Genuity Corp., the Company may, from time to time, sell up to $10 million of common shares ("Common Shares") in the capital of the Company (the "ATM Offering"). The Company intends to use the net proceeds of the ATM Offering, if any, principally for general corporate and working capital requirements, funding ongoing operations (including research and development), to repay indebtedness outstanding from time to time or for other corporate purposes.
Mar 23, 2021 04:11 pm ET
Sona Announces Filing of Preliminary Short Form Base Shelf Prospectus
Halifax, Nova Scotia--(Newsfile Corp. - March 23, 2021) -  Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") a developer of rapid, point-of-care diagnostic texts, has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada. The objective of filing the Shelf Prospectus is to provide the Company with the financial flexibility to take advantage of financing opportunities and favourable market conditions, if and when desired, once the filing is made final.
Feb 26, 2021 02:40 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Feb. 26, 2021 /CNW/ - Trading resumes in:
Feb 26, 2021 02:24 pm ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Feb. 26, 2021 /CNW/ - The following issues have been halted by IIROC:
Feb 19, 2021 09:07 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Feb. 19, 2021 /CNW/ - Trading resumes in:
Feb 19, 2021 09:04 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Feb. 19, 2021 /CNW/ - The following issues have been halted by IIROC:
Feb 18, 2021 02:39 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Feb. 18, 2021 /CNW/ - Trading resumes in:
Feb 18, 2021 02:30 pm ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Feb. 18, 2021 /CNW/ - The following issues have been halted by IIROC:
Feb 18, 2021 01:58 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Feb. 18, 2021 /CNW/ - Trading resumes in:
Feb 18, 2021 01:53 pm ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Feb. 18, 2021 /CNW/ - The following issues have been halted by IIROC:
Feb 02, 2021 09:33 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Feb. 2, 2021 /CNW/ - Trading resumes in:
Feb 02, 2021 09:24 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Feb. 2, 2021 /CNW/ - The following issues have been halted by IIROC:
Jan 29, 2021 02:15 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Jan. 29, 2021 /CNW/ - Trading resumes in:
Jan 29, 2021 02:06 pm ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Jan. 29, 2021 /CNW/ - The following issues have been halted by IIROC:
Jan 18, 2021 09:31 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Jan. 18, 2021 /CNW/ - Trading resumes in:
Jan 18, 2021 09:27 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Jan. 18, 2021 /CNW/ - The following issues have been halted by IIROC:
Jan 04, 2021 12:16 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Jan. 4, 2021 /CNW/ - Trading resumes in:
Jan 04, 2021 12:07 pm ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Jan. 4, 2021 /CNW/ - The following issues have been halted by IIROC:
Dec 31, 2020 09:22 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Dec. 31, 2020 /CNW/ - Trading resumes in:
Dec 31, 2020 09:08 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Dec. 31, 2020 /CNW/ - Trading resumes in:
Dec 31, 2020 09:08 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Dec. 31, 2020 /CNW/ - The following issues have been halted by IIROC:
Dec 31, 2020 09:08 am ET
Sona Nanotech Receives CE Mark Approval for its Rapid COVID-19 Antigen Test
Halifax, Nova Scotia--(Newsfile Corp. - December 31, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, has been granted CE Mark status for its rapid, COVID-19 antigen test. The CE Mark declares the conformity of the Sona test with EU regulations and allows Sona to commercialize its test throughout Europe and potentially other territories in which the CE Mark is recognized.
Dec 31, 2020 09:01 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Dec. 31, 2020 /CNW/ - The following issues have been halted by IIROC:
Dec 31, 2020 08:17 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Dec. 31, 2020 /CNW/ - Trading resumes in:
Dec 31, 2020 07:49 am ET
IIROC Trading Halt - SONA
TORONTO, Dec. 31, 2020 /CNW/ - The following issues have been halted by IIROC:
Dec 16, 2020 09:32 am ET
Sona Nanotech Closes Unbrokered Private Placement Financing for $2.26M in Gross Proceeds
Halifax, Nova Scotia--(Newsfile Corp. - December 16, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, is pleased to announce that it has closed its non-brokered private placement that was announced on December 3, 2020 with the issuance of 2,259,200 units at $1.00 per unit.
Dec 10, 2020 01:09 pm ET
Sona Nanotech Comments on Market Activity
Halifax, Nova Scotia--(Newsfile Corp. - December 10, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, at the request of Investment Industry Regulatory Organization of Canada (IIROC), confirms that it is not aware of any reason for today's increase in market activity in its shares and there has been no material change or information to report under applicable securities laws that would account for today's trading activity in its common shares.
Dec 10, 2020 11:42 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Dec. 10, 2020 /CNW/ - Trading resumes in:
Dec 10, 2020 11:28 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Dec. 10, 2020 /CNW/ - The following issues have been halted by IIROC:
Dec 10, 2020 11:03 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Dec. 10, 2020 /CNW/ - Trading resumes in:
Dec 10, 2020 10:37 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Dec. 10, 2020 /CNW/ - The following issues have been halted by IIROC:
Dec 08, 2020 09:35 am ET
Sona Nanotech $2M Private Placement Financing Fully Subscribed
Halifax, Nova Scotia--(Newsfile Corp. - December 8, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, is pleased to announce that its previously announced non-brokered private placement for up to $2,00,000 is now fully subscribed. The Company expects to close the Financing shortly.
Dec 03, 2020 09:00 am ET
Sona Nanotech Arranges Private Placement Financing and Appoints EU Agent for Application for CE Mark
Halifax, Nova Scotia--(Newsfile Corp. - December 3, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, is pleased to announce that it plans to raise up to $2,000,000 through a non-brokered private placement (the "Financing") of up to 2,000,000 units of Sona (each, a "Unit") at $1.00 per Unit. Each Unit will consist of one common share of Sona (a "Common Share") and one-half of a Common Share purchase warrant (each whole Common Share purchase warrant, a "Warrant"). Each Warrant will be exercisable to purchase one additional Common Share of Sona at a price of $1.25 per Common Share for a period of 24 months from the closing date of the Financing (the "Closing Date").
Nov 30, 2020 08:58 am ET
Sona Nanotech Provides Corporate Update
Halifax, Nova Scotia--(Newsfile Corp. - November 30, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, received further feedback from Health Canada, subsequent to its withdrawal of its application for an Interim Order authorization ("IO") for the marketing of its rapid, COVID-19 antigen test. As part of its review, Health Canada commissioned an evaluation from the National Microbiology Laboratory (NML) whose evaluation produced discordant results to the Company's prior analytical and clinical studies conducted by MRIGlobal and SaudiVax.
Nov 25, 2020 01:50 pm ET
Sona Nanotech Withdraws Rapid COVID-19 Antigen Test Application Based on Feedback from Health Canada
Halifax, Nova Scotia--(Newsfile Corp. - November 25, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, withdrew its application for an Interim Order authorization ("IO") from Health Canada for the marketing of its rapid, COVID-19 antigen test in order to obtain more clinical data to augment its submission. The Company is committed to working with regulators to provide additional information and analysis on its test and to re-submitting its application as quickly as possible.
Nov 25, 2020 01:08 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Nov. 25, 2020 /CNW/ - Trading resumes in:
Nov 25, 2020 07:48 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Nov. 25, 2020 /CNW/ - The following issues have been halted by IIROC:
Nov 09, 2020 02:18 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Nov. 9, 2020 /CNW/ - Trading resumes in:
Nov 09, 2020 02:09 pm ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Nov. 9, 2020 /CNW/ - The following issues have been halted by IIROC:
Nov 09, 2020 11:41 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Nov. 9, 2020 /CNW/ - Trading resumes in:
Nov 09, 2020 11:35 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Nov. 9, 2020 /CNW/ - The following issues have been halted by IIROC:
Nov 09, 2020 09:52 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Nov. 9, 2020 /CNW/ - Trading resumes in:
Nov 09, 2020 09:45 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Nov. 9, 2020 /CNW/ - The following issues have been halted by IIROC:
Nov 09, 2020 08:52 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Nov. 9, 2020 /CNW/ - Trading resumes in:
Nov 09, 2020 08:47 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Nov. 9, 2020 /CNW/ - The following issues have been halted by IIROC:
Nov 03, 2020 08:18 am ET
Sona Nanotech Appoints New Director
Halifax, Nova Scotia--(Newsfile Corp. - November 3, 2020) - Sona Nanotech Inc. (CSE: SONA) (the "Company") is pleased to announce the appointment of Mr. J. Mark Lievonen, C.M., to the Company's Board of Directors. Mr. Lievonen is the former President of Sanofi Pasteur Limited, the Canadian vaccine division of Sanofi. Under his leadership, Sanofi Pasteur became a billion dollar enterprise in Canada, manufacturing over 50 million doses of vaccines for both domestic and international markets. Mr. Lievonen spearheaded a cancer vaccine program and supported the launch of a five-component pertussis vaccine, which is widely used to this day. He has also served on a number of public and not-for-profit boards and industry organizations including as Chair of BIOTECanada and Rx&D (now Innovative Medicines Canada).
Oct 29, 2020 10:47 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Oct. 29, 2020 /CNW/ - Trading resumes in:
Oct 29, 2020 10:03 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Oct. 29, 2020 /CNW/ - The following issues have been halted by IIROC:
Oct 29, 2020 09:59 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Oct. 29, 2020 /CNW/ - Trading resumes in:
Oct 29, 2020 09:46 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Oct. 29, 2020 /CNW/ - The following issues have been halted by IIROC:
Oct 29, 2020 09:16 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Oct. 29, 2020 /CNW/ - Trading resumes in:
Oct 29, 2020 08:38 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Oct. 29, 2020 /CNW/ - The following issues have been halted by IIROC:
Oct 29, 2020 08:38 am ET
Sona Nanotech Receives 'Deprioritization' from FDA; Health Canada Evaluation Continues
Halifax, Nova Scotia--(Newsfile Corp. - October 29, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, received notice from the FDA that the Company's request for an emergency use authorization ("EUA") for the marketing of its rapid COVID-19 antigen test in the United States "is not a priority" and consequently such authorization will not be issued at this time. The FDA cited current EUA request prioritization criteria as including "the public health need for the product" and did not comment on the performance of the Sona test.
Sep 29, 2020 01:04 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Sept. 29, 2020 /CNW/ - Trading resumes in:
Sep 29, 2020 01:00 pm ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Sept. 29, 2020 /CNW/ - The following issues have been halted by IIROC:
Aug 31, 2020 12:20 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Aug. 31, 2020 /CNW/ - Trading resumes in:
Aug 31, 2020 12:12 pm ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Aug. 31, 2020 /CNW/ - The following issues have been halted by IIROC:
Aug 31, 2020 08:15 am ET
Sona Engages Sports Marketing Partner to Secure Concussion Test Development Partner
Halifax, Nova Scotia--(Newsfile Corp. - August 31, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, announced today it has engaged Bonham/Wills & Associates ("Bonham/Wills"), a leading sports consulting firm, to assist in securing test development sponsorship partners for its next rapid-response test R&D project, leveraging the Company's proprietary gold nanorod technology. Bonham/Wills is tasked with identifying partners to participate in the development of a prototype and eventual field validation for a test for mild-traumatic brain injury ("mTBI"), commonly referred to as concussion. Partners will be asked to support on-going test development, optimization, validation and field studies with a view to obtaining regulatory approval around the globe.
Aug 27, 2020 10:09 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Aug. 27, 2020 /CNW/ - Trading resumes in:
Aug 27, 2020 10:01 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Aug. 27, 2020 /CNW/ - The following issues have been halted by IIROC:
Aug 25, 2020 02:25 pm ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Aug. 25, 2020 /CNW/ - The following issues have been halted by IIROC:
Aug 25, 2020 01:52 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Aug. 25, 2020 /CNW/ - Trading resumes in:
Aug 25, 2020 01:34 pm ET
Sona Nanotech Announces Clinical Evaluation Study Results for its COVID-19 Antigen Test
Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, is pleased to announce that its rapid detection COVID-19 antigen test achieved a sensitivity of 84.6% and a specificity of 90.0% in a study across 99 collected clinical patient samples, which included 39 positive samples and 60 negative samples, as determined by RT-PCR testing. The Company is now continuing its submission of data to both the FDA and Health Canada to support their requirements for emergency use authorization approvals.
Aug 25, 2020 10:52 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Aug. 25, 2020 /CNW/ - The following issues have been halted by IIROC:
Aug 20, 2020 11:34 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Aug. 20, 2020 /CNW/ - Trading resumes in:
Aug 20, 2020 11:25 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Aug. 20, 2020 /CNW/ - The following issues have been halted by IIROC:
Aug 20, 2020 10:23 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Aug. 20, 2020 /CNW/ - Trading resumes in:
Aug 20, 2020 10:11 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Aug. 20, 2020 /CNW/ - The following issues have been halted by IIROC:
Aug 20, 2020 09:38 am ET
Sona Nanotech Clinical In-Field Validation Study Results to Be Released Next Week
Halifax, Nova Scotia--(Newsfile Corp. - August 20, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, announces that it expects to release a report on its clinical, in-field evaluation studies for its rapid detection, COVID-19 antigen test next week. This data will be used to support the Company's submissions to Health Canada and the FDA for emergency use authorization ("EUA") approval for its COVID-19 antigen test.
Aug 17, 2020 10:15 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Aug. 17, 2020 /CNW/ - Trading resumes in:
Aug 17, 2020 10:12 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Aug. 17, 2020 /CNW/ - The following issues have been halted by IIROC:
Aug 06, 2020 02:36 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, Aug. 6, 2020 /CNW/ - Trading resumes in:
Aug 06, 2020 02:31 pm ET
IIROC Trading Halt - SONA
VANCOUVER, BC, Aug. 6, 2020 /CNW/ - The following issues have been halted by IIROC:
Aug 06, 2020 01:51 pm ET
Sona Nanotech Updates on Timing of Clinical In-Field Validation Studies for its COVID-19 Antigen Test
Halifax, Nova Scotia--(Newsfile Corp. - August 6, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, announces that its previously announced clinical, in-field evaluation studies for its rapid detection, COVID-19 antigen test that commenced in July continue and are now expected to return their full results within two weeks. The delays have been due to ethics review board approvals and a need to make study modifications to accommodate regulatory updates, including for study enrolment criteria and assessment at point of care settings, as well as for test handling procedures.
Jul 28, 2020 03:27 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, July 28, 2020 /CNW/ - Trading resumes in:
Jul 28, 2020 03:23 pm ET
IIROC Trading Halt - SONA
VANCOUVER, BC, July 28, 2020 /CNW/ - The following issues have been halted by IIROC:
Jul 28, 2020 02:44 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, July 28, 2020 /CNW/ - Trading resumes in:
Jul 28, 2020 02:37 pm ET
IIROC Trading Halt - SONA
VANCOUVER, BC, July 28, 2020 /CNW/ - The following issues have been halted by IIROC:
Jul 28, 2020 01:57 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, July 28, 2020 /CNW/ - Trading resumes in:
Jul 28, 2020 01:48 pm ET
IIROC Trading Halt - SONA
VANCOUVER, BC, July 28, 2020 /CNW/ - The following issues have been halted by IIROC:
Jul 23, 2020 03:03 pm ET
Sona Nanotech Unaware of Any Material Change
Halifax, Nova Scotia--(Newsfile Corp. - July 23, 2020) - At the request of the Investment Industry Regulatory Organization of Canada ("IIROC") Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity.
Jul 09, 2020 08:00 am ET
RETRANSMISSION: Sona Nanotech Engages Maxim Group for NASDAQ Listing and Investment Banking Services, and Announces Organizational Change
Halifax, Nova Scotia--(Newsfile Corp. - July 9, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) ("Sona Nanotech" or the "Company"), a developer of rapid, point-of-care diagnostic tests for COVID-19 and other applications, has engaged Maxim Group, LLC ("Maxim") for general financial advisory and investment banking services in relation to its planned application to list the Company's common shares on the NASDAQ Capital Market ("NASDAQ").
Jul 08, 2020 06:41 pm ET
Sona Nanotech Engages Maxim Group for NASDAQ Listing and Investment Banking Services, and Announces Organizational Change
Halifax, Nova Scotia--(Newsfile Corp. - July 8, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) ("Sona Nanotech" or the "Company"), a developer of rapid, point-of-care diagnostic tests for COVID-19 and other applications, has engaged Maxim Group, LLC ("Maxim") for general financial advisory and investment banking services in relation to its planned application to list the Company's common shares on the NASDAQ Capital Market ("NASDAQ").
Jul 03, 2020 10:57 am ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, July 3, 2020 /CNW/ - Trading resumes in:
Jul 03, 2020 10:51 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, July 3, 2020 /CNW/ - The following issues have been halted by IIROC:
Jul 02, 2020 04:06 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, BC, July 2, 2020 /CNW/ - Trading resumes in:
Jul 02, 2020 02:52 pm ET
Sona Nanotech Announces Validation Results for its COVID-19 Antigen Test
Halifax, Nova Scotia--(Newsfile Corp. - July 2, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, is pleased to announce that its rapid detection, COVID-19 antigen test's laboratory validation studies of performance levels have resulted in a test sensitivity of 96%, test specificity of 96% and a Limit of Detection ("LOD") of 2.1 x 102 TCID50. Sales of the tests will now be permitted under a 'research use only' label until full regulatory authority is granted, in relevant territories, at which time the 'research use only' label requirement would be lifted, as discussed below. Technology transfer to manufacturers is currently underway to produce tests to meet current and expected demand. The Company will provide an update on sales progress and manufacturing delivery timetables in the coming weeks.
Jul 02, 2020 09:03 am ET
IIROC Trading Halt - SONA
VANCOUVER, BC, July 2, 2020 /CNW/ - The following issues have been halted by IIROC:
Jun 01, 2020 09:54 am ET
IIROC Trade Resumption - SONA
VANCOUVER, June 1, 2020 /CNW/ - Trading resumes in:
Jun 01, 2020 09:50 am ET
Sona Nanotech Comments on Trading Activity at Request of IIROC
Halifax, Nova Scotia--(Newsfile Corp. - June 1, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company") has been requested by the Investment Industry Regulatory Organization of Canada (IIROC) to comment on the recent increase in the trading volume and price of the Company's common shares. The Company is not aware of any material change in its business or affairs that has not been publicly disclosed that would account for the recent increase in market activity.
Jun 01, 2020 09:43 am ET
IIROC Trading Halt - SONA
VANCOUVER, June 1, 2020 /CNW/ - The following issues have been halted by IIROC:
May 22, 2020 07:00 am ET
Sona Nanotech Engages MRIGlobal for COVID-19 Test Validation Studies
Halifax, Nova Scotia--(Newsfile Corp. - May 22, 2020) -  Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company") is pleased to announce the engagement of MRIGlobal, a leading applied scientific research organization, to provide analytical and clinical validation studies for Sona's COVID-19 rapid detection, point-of-care, antigen test which will be used for submission to Health Canada for regulatory approval and the FDA for Emergency Use Authorization (EUA). MRIGlobal has three ISO 9001, CLIA certified, and FDA compliant BSL-3 laboratories located throughout the United States and works with government and corporate clients from around the world.
May 12, 2020 07:28 am ET
Sona Nanotech Provides COVID-19 Antigen Test Progress Update
Halifax, Nova Scotia--(Newsfile Corp. - May 12, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company") is pleased to provide the following update on the development of its rapid-response, COVID-19 antigen test. The Company received confirmation from an independent laboratory that its test achieved a positive response to a recombinant whole spike protein control reagent specific to SARS-CoV2 and matched the limit of detection (LOD) achieved in its own labs. In-house analytical testing has indicated a very high level of specificity to COVID-19, with no false positives being generated.
Apr 15, 2020 01:28 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, April 15, 2020 /CNW/ - Trading resumes in:
Apr 15, 2020 01:21 pm ET
IIROC Trading Halt - SONA
VANCOUVER, April 15, 2020 /CNW/ - The following issues have been halted by IIROC:
Apr 13, 2020 07:05 am ET
Sona Nanotech Provides a Progress Update on its Covid-19 Antigen Test
Halifax, Nova Scotia--(Newsfile Corp. - April 13, 2020) -  Sona Nanotech Inc. (CSE: SONA) (OTC PINK: SNANF) (the "Company") is pleased to provide an update on the development, manufacturing arrangements and pre-orders for its Covid-19 antigen test. The Company this past week has:
Apr 03, 2020 02:44 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, April 3, 2020 /CNW/ - Trading resumes in:
Apr 03, 2020 02:35 pm ET
IIROC Trading Halt - SONA
VANCOUVER, April 3, 2020 /CNW/ - The following issues have been halted by IIROC:
Mar 31, 2020 04:32 pm ET
Sona Nanotech Awarded $4.1 Million from NGen for Rapid Development and Launch of COVID-19 Antigen Test
Halifax, Nova Scotia--(Newsfile Corp. - March 31, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTC Pink: SNANF) (the "Company") is pleased to announce that it has been awarded a $4.1 million grant from NGen, Canada's Advanced Manufacturing Supercluster, to develop and commercialize its Covid-19 rapid-response antigen test. This non-repayable grant will be used to accelerate the development of a prototype and scale manufacturing capabilities with a view to deploying this Covid-19 virus-detecting, point-of-care test with Canadian medical authorities as soon as possible.
Mar 30, 2020 01:10 pm ET
IIROC Trade Resumption - SONA
VANCOUVER, March 30, 2020 /CNW/ - Trading resumes in:
Mar 30, 2020 01:00 pm ET
Sona Nanotech Enters into a Manufacturing Service Agreement and a Sale Letter of Intent Agreement for 2mm Tests
Halifax, Nova Scotia--(Newsfile Corp. - March 30, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTC Pink: SNANF) (the "Company") entered into service and supply agreements with a contract manufacturing organization (CMO) in Europe for the manufacture of its Covid-19 virus-detecting, rapid-response test. The Company also entered into a letter of intent agreement with an international distributor representing the health authority of a G20 country for the purchase of 2,000,000 test kits. The Company cautions that its test is still in development but expects to complete a functional prototype and confirm third party validation tests in the near future. R&D work is being done in Germany and Scotland, with consortium partners, and at the Company's lab in Dartmouth, Nova Scotia where qualified laboratory technicians are working with samples of the virus' antigen and antibodies, under the supervision of the Company's Chief Technology Officer, Head of R&D, and President and CEO. The Company expects to benefit from the regulatory relief offered by the FDA to expedite the availability of diagnostics associated with the Covid-19 disease, subject to certain conditions.
Mar 30, 2020 08:36 am ET
IIROC Trading Halt - SONA
VANCOUVER, March 30, 2020 /CNW/ - The following issues have been halted by IIROC:
Mar 20, 2020 08:10 am ET
Sona Nanotech Obtains New OTC Trading Symbol
Halifax, Nova Scotia--(Newsfile Corp. - March 20, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTC Pink: SNANF) (the "Company") is pleased to announce that it has undertaken to further develop the U.S. trading market for its common shares. As a first step, Sona recently applied for a new OTC trading symbol that will more accurately reflect the company's current name and business. At the market open today, the symbol was changed from "LMTCF" to "SNANF". Investors, brokers and other market participants should take note of this change.
Mar 19, 2020 07:30 am ET
RETRANSMISSION: Sona Achieves Significant Milestone in Covid-19 Test Development
Halifax, Nova Scotia--(Newsfile Corp. - March 19, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTC PINK: LMTCF) ("Sona") is pleased to provide an update on the development of its rapid-response Covid-19 test. Sona is leading a consortium of diagnostic test developers including GE Healthcare Life Sciences, to create a rapid-response, lateral flow test that will directly identify the Covid-19 virus and provide in-field test results in minutes, without the use of specialized laboratory equipment or technicians.
Mar 18, 2020 06:06 pm ET
Sona Achieves Significant Milestone in Covid-19 Test Development
Halifax, Nova Scotia--(Newsfile Corp. - March 18, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTC Pink: LMTCF) ("Sona") is pleased to provide an update on the development of its rapid-response Covid-19 test. Sona is leading a consortium of diagnostic test developers including GE Healthcare Life Sciences, to create a rapid-response, lateral flow test that will directly identify the Covid-19 virus and provide in-field test results in minutes, without the use of specialized laboratory equipment or technicians.
Mar 17, 2020 08:44 am ET
Sona Nanotech Grants Options
Halifax, Nova Scotia--(Newsfile Corp. - March 17, 2020) - Sona Nanotech Inc. (CSE: SONA) (the "Company") is pleased to announce that it has granted 1,100,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") of which 550,000 have been granted to Directors and Officers. Each option is exercisable into one common share at a price of $0.60 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company's Stock Option Plan.
Mar 12, 2020 07:30 am ET
Sona Provides Corporate Update
Halifax, Nova Scotia--(Newsfile Corp. - March 12, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTC Pink: LMTCF) ("Sona") is pleased to provide a corporate update on recent activities. In the past several weeks, Sona has been focused on work related to the development of a rapid response COVID-19 lateral flow test. This update will outline progress and advancements on Sona's COVID-19 test and other corporate developments.
Mar 06, 2020 07:52 am ET
Sona Provides Update on Coronavirus Rapid Screening Test and Announces Scientific Advisors
Halifax, Nova Scotia--(Newsfile Corp. - March 6, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTC: LMTCF) ("Sona") is pleased to provide an update on its Covid-19 rapid screening test as well as announcing the addition of Fiona Marshall and Sandy Morrison as scientific advisors for the Covid-19 test development.
Mar 04, 2020 10:44 am ET
IIROC Trade Resumption - SONA
VANCOUVER, March 4, 2020 /CNW/ - Trading resumes in:
Mar 04, 2020 07:00 am ET
Sona Partners With GE Healthcare Life Sciences to Complete Coronavirus Rapid Screening Test
Halifax, Nova Scotia--(Newsfile Corp. - March 4, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTC PINK: LMTCF) ("Sona") and GE Healthcare Life Sciences will jointly complete test development of the Sona Covid-19 Coronavirus rapid response lateral flow test, and will use GE Healthcare Life Sciences' Fast Flow High Performance Membrane (FFHP) in production of the test. Sona will retain all commercial rights to the resulting test.
Mar 03, 2020 02:56 pm ET
Sona Partners with GE Healthcare Life Sciences to Complete Coronavirus Rapid Screening Test
Halifax, Nova Scotia--(Newsfile Corp. - March 3, 2020) - Sona Nanotech Inc. (CSE: SONA) ("Sona") and GE Healthcare Life Sciences will jointly complete test development of the Sona Covid-19 Coronavirus rapid response lateral flow test, and will use GE Healthcare Life Sciences' Fast Flow High Performance Membrane (FFHP) in production of the test. Sona will retain all commercial rights to the resulting test.
Mar 03, 2020 08:25 am ET
IIROC Trading Halt - SONA
VANCOUVER, March 3, 2020 /CNW/ - The following issues have been halted by IIROC:
Feb 18, 2020 07:30 am ET
Sona Announces Data Partnership for Covid-19 Rapid Screening Test
Halifax, Nova Scotia--(Newsfile Corp. - February 18, 2020) - Sona Nanotech Inc. (CSE: SONA) has announced a partnership with UK-based medical technology company Bond Digital Health (Bond) to add data capture and analysis to its coronavirus (Covid-19) rapid screening test currently in development.
Feb 13, 2020 08:00 am ET
Sona announces key partner for Coronavirus Rapid Screening Test
Halifax, Nova Scotia--(Newsfile Corp. - February 13, 2020) - Sona Nanotech Inc.  (CSE: SONA)  ("Sona") has secured an agreement with The Native Antigen Company ("Native") to supply biologics for the recently announced Covid-19 Coronavirus rapid screening test, currently in development by Sona (See Sona news release dated February 10, 2020).
Feb 10, 2020 07:30 am ET
Sona Develops Rapid Screening Test for Coronavirus
Halifax, Nova Scotia--(Newsfile Corp. - February 10, 2020) - Sona Nanotech Inc. ("Sona") (CSE: SONA) is deploying its proprietary nanotechnology in the development of a rapid screening test for the current Coronavirus, "nCoV19". Sona is developing a quick-response lateral flow test to screen patients for the nCoV19 virus. When completed, the test is expected to produce results in 5-15 minutes and is anticipated to cost less than $50. There is currently no lateral flow test specific to the nCoV19 strain of the Coronavirus, which was first detected in Wuhan, Hubei Province, China and continues to spread across the globe.
Jan 14, 2020 06:00 am ET
Sona Announces Conversion of Notes Payable
Halifax, Nova Scotia--(Newsfile Corp. - January 14, 2020) - Sona Nanotech Inc. (CSE: SONA) ("Sona" or the "Company"): The Company is converting notes payable of $95,000 and accrued interest of $67,322 owed to certain non-arm's length note holders and notes payable of $200,000 and accrued interest of $141,732 owed to certain arm's length note holders. The notes payable will be settled in full by the issuance to these note holders of an aggregate of 2,520,270 common shares at a deemed price of $0.20 per share.
Dec 19, 2019 04:24 pm ET
Sona Nanotech Appoints New Director
Halifax, Nova Scotia--(Newsfile Corp. - December 19, 2019) - Sona Nanotech Inc. (CSE: SONA) (the "Company") is pleased to announce the appointment of Mr. Jim Megann to the Company's Board of Directors. Mr. Megann is a former director of the Company and is currently the Managing Director of Numus Financial. Numus Financial has been an investor in Sona Nanotech since 2014.
Aug 16, 2019 11:00 am ET
Antler Gold announces closing of the purchase of mineral assets from Sona Nanotech
HALIFAX, Aug. 16, 2019 /CNW/ - Antler Gold Inc. ("Antler") (TSXV: ANTL) and Sona Nanotech Inc. ("Sona") (CSE: SONA) are pleased to announce that Antler has acquired from Sona a 100% interest in certain mineral claims comprising the Crescent Lake/KM61 molybdenum-copper-silver project located in Armstrong, Ontario (the "Property"), as announced in a press release dated May 15, 2019.
Aug 06, 2019 08:30 am ET
Sona Nanotech Inc. and Expedeon AG Strengthen Partnership to Improve Global Market Offering
Diagnostics companies sign new commercial agreement to address limitations in development of multiplex point-of-care lateral flow assay diagnostic tests
Jul 16, 2019 08:00 am ET
Sona Announces Debt Settlements with Creditors
Halifax, Nova Scotia--(Newsfile Corp. - July 16, 2019) - Sona Nanotech Inc. (CSE: SONA) ("Sona" or the "Company") has arranged a debt settlement of $797,953 in amounts owed to certain non-arm's length creditors and included in accounts payable to related parties in the financial statements of Sona (the "Debts"). The Debts will be settled in full by the issuance to these creditors of an aggregate of 3,199,812 common shares at a deemed price of $0.25 per share. The Company also arranged a debt conversion of $137,093 in debt owed to an arm's length creditor as shown in the financial statements of Sona (the "Convertible Debt"). The Convertible Debt will be settled in full based on its conversion price of $0.158 per share resulting in the issuance of 867,677 common shares to the debt holder.
Jun 14, 2019 09:00 am ET
Antler Purchases Subsidiaries from Sona Nanotech
HALIFAX, June 14, 2019 /CNW/ - Antler Gold Inc. ("Antler") (TSXV: ANTL) and Sona Nanotech Inc. ("Sona") (CSE: SONA) are pleased to announce that they have closed Antler's acquisition of two subsidiaries of Sona that own technical and physical data on historical mineral interests in Mexico, and associated offsetting intercompany receivables, for a purchase price of $1.00 (the "Transaction"), as previously announced. The assets and third party liabilities are nominal for both subsidiaries. 
May 16, 2019 08:30 am ET
Antler Gold Agrees to Purchase Mineral Assets from Sona Nanotech
Halifax, Nova Scotia--(Newsfile Corp. - May 16, 2019) - Antler Gold Inc. (TSXV: ANTL) ("Antler") and Sona Nanotech Inc. (CSE: SONA) ("Sona") are pleased to announce that they have entered into an agreement pursuant to which Antler will acquire from Sona a 100% interest in certain mineral claims comprising the Crescent Lake/KM61 molybdenum-copper-silver project located in Armstrong, Ontario (the "Property").
May 15, 2019 04:30 pm ET
Antler Gold agrees to purchase mineral assets from Sona Nanotech
HALIFAX, May 15, 2019 /CNW/ - Antler Gold Inc. ("Antler") (TSXV: ANTL) and Sona Nanotech Inc. ("Sona") (CSE: SONA) are pleased to announce that they have entered into an agreement pursuant to which Antler will acquire from Sona a 100% interest in certain mineral claims comprising the Crescent Lake/KM61 molybdenum-copper-silver project located in Armstrong, Ontario (the "Property").
May 09, 2019 08:30 am ET
Sona Nanotech Inc. Announces Collaboration with University of Birmingham
Halifax, Nova Scotia--(Newsfile Corp. - May 9, 2019) - Sona Nanotech Inc.'s (CSE: SONA) mission to advance medical diagnostics took a step forward today with the announcement of a collaboration with the University of Birmingham in the UK to develop next generation nanorods for tissue imaging.
Mar 12, 2019 08:30 am ET
Sona Nanotech Inc. Signs Agreement to Develop Innovative New Point of Care Tests for Infectious Diseases
Halifax, Nova Scotia--(Newsfile Corp. - March 12, 2019) - Sona Nanotech Inc. (CSE: SONA) has signed a collaboration agreement with a UK medical diagnostics company to develop new highly sensitive point of care diagnostic tests for infectious diseases.
Mar 07, 2019 08:30 am ET
Sona Nanotech Announces Collaboration with Leading Diagnostic Company to Improve Performance of Foodborne Pathogen Tests
Halifax, Nova Scotia--(Newsfile Corp. - March 7, 2019) - Sona Nanotech Inc. (CSE: SONA) today announced a collaboration with global diagnostics solutions provider Romer Labs to improve performance in their RapidChek® SELECT™ pathogen test kits.
Jan 21, 2019 08:23 am ET
Sona Nanotech Grants Options
Halifax, Nova Scotia--(Newsfile Corp. - January 21, 2019) - Sona Nanotech Inc. (CSE: SONA) (the "Company") is pleased to announce that it has granted 1,410,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") of which 850,000 have been granted to Directors and Officers. Each option is exercisable into one common share at a price of $0.35 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company's Stock Option Plan.
Jan 16, 2019 09:00 am ET
Sona Nanotech Inc. Announces Collaboration with Anteo Technologies;
Innovative companies combine technologies to speed up lateral flow assay development time
Dec 04, 2018 08:30 am ET
Collaboration with Major European Lateral Flow Test Developer and Sona Nanotech Inc.
Halifax, Nova Scotia--(Newsfile Corp. - December 4, 2018) - Sona Nanotech Inc. (CSE: SONA) has signed a collaboration agreement with one of Europe's largest lateral flow test developers, who will integrate Sona's nanorod technology into their market-established lateral flow assays.
Nov 22, 2018 08:30 am ET
Business Growth Spurs Expansion to Larger Lab Facilities in Halifax for Sona Nanotech Inc.
Halifax, Nova Scotia--(Newsfile Corp. - November 22, 2018) - Sona Nanotech Inc. (CSE: SONA) has relocated its laboratory facilities to Halifax as it seeks to capitalise on recent business success and further expand its business in the diagnostics market.
Nov 08, 2018 08:30 am ET
Sona Nanotech Inc. Engages Gold and Nanotech Expert to Develop Business in Europe
UK-based consultant Trevor Keel has a degree in chemistry from the University of Kent, a PhD in nanotechnology from the University of Nottingham and a master's degree in management from University College London.
Oct 25, 2018 08:00 am ET
Sona Nanotech Inc. signs co-marketing agreement with Bond Digital Health
Halifax, Nova Scotia--(Newsfile Corp. - October 25, 2018) - Sona Nanotech Inc. (CSE: SONA) today announced it has signed a co-marketing agreement with UK-based digital healthcare company Bond Digital Health.
Oct 17, 2018 08:00 am ET
Sona Nanotech Inc. announces collaboration with Soma BioScience to produce new diagnostic tests
Halifax, Nova Scotia--(Newsfile Corp. - October 17, 2018) - Sona Nanotech Inc. (CSE: SONA) today announced a collaboration with Soma BioScience (Soma) to produce new diagnostic tests.
Oct 11, 2018 07:59 am ET
Distribution and Development Agreement Signed Between Sona Nanotech Inc.and Expedeon
Halifax, Nova Scotia--(Newsfile Corp. - October 11, 2018) - Sona Nanotech Inc. (CSE: SONA) today announced the signing of an agreement with global biotech company Expedeon Ltd. (FSE: EXN) for the supply of Sona's unique gold nanorods for integration into Expedeon's product range.
Oct 09, 2018 09:10 am ET
CSE New Listing - Sona Nanotech Inc. Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2018) - Sona Nanotech (CSE: SONA) is one of the latest new listing on the Canadian Securities Exchange, having previously traded on the TSX Venture Exchange as Stockport Exploration. Halifax-based Sona is a nano technology life sciences firm that has developed two proprietary methods for the manufacture of rod shaped gold nanoparticles.
Oct 04, 2018 08:00 am ET
Sona Nanotech Inc. Announces Listing on Canadian Securities Exchange
Halifax, Nova Scotia--(Newsfile Corp. - October 4, 2018) - Sona Nanotech Inc. (CSE: SONA) ("Sona" or the "Company") is pleased to announce that the Canadian Securities Exchange (CSE) has approved the Company's application to list its common shares on the CSE. Effective October 4, 2018, the Company's shares will commence trading on the CSE under the symbol "SONA".